Filip De Vos

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 753 citations

Medicine, Oncology, Pharmacotherapy +16

Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer

Ryan B. Corcoran, Thierry André, Chloé E. Atreya et al. · Cancer Discovery · 2018 · 583 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter

Michael Lim, Michael Weller, Ahmed Idbaïh et al. · Neuro-Oncology · 2022 · 501 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg et al. · Nature Medicine · 2023 · 298 citations · Full text

Medicine, Oncology, Pharmacology +16

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Karel Decaestecker, Gert De Meerleer, Bieke Lambert et al. · Radiation Oncology · 2014 · 257 citations · Full text

Medicine, Oncology, Radiation Oncology +17